Efficacy and Safety Study of Aprepitant Injection for Prevention of Post-operative Nausea and Vomiting

Phase 3 Not yet recruiting 486 enrolled CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.

RandomizedParallel-groupQuadruple-blindTreatment

Summary

A randomized, double-blind, placebo-controlled, multi-center phase III study to compare the efficacy and safety of aprepitant injection and placebo in the prevention of post-operative nausea and vomiting (PONV).,

Timeline

Start: 2024-10-28
Primary completion: 2026-03-28
Completion: 2026-03-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aprepitant	Other / unclassified	32 mg	Intravenous

Indications

No indication recorded.